By Tina Phan ’26

In November 2022, a coalition of anti-abortion activists banded forth to file a lawsuit against the U.S. Food and Drug Administration (FDA) over one drug — mifepristone, known as the abortion pill. Mifepristone is the first drug used in a two-part regimen to terminate a pregnancy within ten weeks of gestation. The drug serves as an inhibitor of progesterone, a hormone which supports the development of a fetus through the thickening of the uterine lining. The second drug in the two-part regimen is misoprostol which expels uterine content. FDA-approved for over two decades, the generic form of mifepristone has over a 99 percent safety record and has been employed for over half of the abortions since 2000 according to the Guttmacher Institute. 

In November of 2022, the coalition “Alliance for Hippocratic Medicine,” (AHM) sought to challenge the FDA’s decision to approve mifepristone. The organization also argued for the withdrawal of recent regulations implemented to promote accessibility of the abortion pill. Several months after filing the lawsuit, AHM’s case was considered in March 2023 by U.S. District Judge Matthew Kacsmaryk for the Northern District of Texas, an official who was appointed by former President Trump in 2019. Many of the AHM lawsuit’s claims targeted the procedural grounds of approval for mifepristone, arguing that the FDA was not thorough in reviewing the drug before approval. However, the initial approval of mifepristone in 2000 was not the last time the drug was reviewed; the drug was approved twice again in 2016 and early 2023. The AHM also attacked the expedited approval under Subpart H, however the need for abortion pills and the extensive FDA studies justified the use of such a provision.  The AHM lawsuit also requested the Court to issue “a preliminary and permanent injunction ordering Defendants [FDA] to withdraw mifepristone and misoprostol as FDA-approved medical abortion drugs and to withdraw Defendants’ actions to deregulate these medical abortion drugs.” The plaintiffs’ request for such injunctions would require the immediate withdrawal of the approval for mifepristone and, with that, the immediate halt of the sale, distribution, and dispensing of a drug that had been FDA-approved for decades — an entirely unprecedented move. 

The FDA made it evident that to pull such a long-approved drug from the market could upend both previous precedent and stability amongst the gold-standard system of food and drug approval in the U.S. “Public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for twenty-two years,” argued lawyers for the FDA. Despite the FDA’s argument for precedent, Judge Kacsmaryk ruled on April 7, 2023 that the FDA approval for mifepristone would be suspended. The judge also issued a preliminary injunction in the case, yet allowed seven days for the federal government to appeal before the ruling and injunction would be effective. Less than 24 hours later, however, U.S. District Judge Thomas Rice for the Eastern District of Washington ruled that the FDA may not withdraw access to mifepristone and that the status of the drug would remain unchanged in 17 states and Washington D.C. — all jurisdictions where Democrats had sued to protect mifepristone. Several days later, a 5th Circuit ruling allowed mifepristone to remain on the market. However, the ruling restricted the accessibility of mifepristone, as use of the drug would be prohibited after seven weeks of gestation and no distribution by mail or by certified pharmacies would be available. The FDA & Danco finally filed an emergency appeal with the highest court in the nation — the Supreme Court. 

They requested that either the Supreme Court take on the AHM vs. FDA case on a fast-tracked, fact-based basis or order an administrative stay on Judge Kacsmaryk’s ruling pending the appeal. Justice Alito, who oversees the 5th Circuit of Appeal, granted the administrative stay initially through April 19, but later extended the stay to April 21.  Ultimately, on April 21, SCOTUS released a ruling on the access and approval of mifepristone, stating that the status of both would remain unchanged from their current state. The Supreme Court’s ruling, however, is not the end; SCOTUS has simply sent the case back to the Fifth Circuit as the appeals for the preliminary injunction ordered by Judge Kacsmaryk must still be heard. This expedited hearing is set to occur on May 17, 2023. 

From the Biden administration and the FDA, the message is clear. “If this ruling were to stand, then there will be virtually no prescription, approved by the FDA, that would be safe from these kinds of political, ideological attacks,” President Biden expressed in a statement released on April 7. Medical providers are also concerned that other long-approved medications may be legally contested as precedent surrounding FDA-approved medication potentially shifts. Across the country, the possible prohibition of mifepristone would be detrimental to female citizens’ bodily rights, and accessibility to abortions would diminish. 

Leave a Reply

Trending